Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of Wnt signaling promotes olaparib resistant ovarian cancer

10 Jun 2019

Abstract excerpt

Epithelial ovarian cancer (EOC) has one of the highest death to incidence ratios among all cancers. High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype due to the lack of therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)-ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31219654
DOI: 10.1002/mc.23064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of Wnt signaling promotes olaparib resistant ovarian cancerPMID 31219654Read ↗

Targeting Wnt Signaling To Overcome PARP Inhibitor ResistanceSemantic proximity Read ↗

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway InhibitorsSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive reviewSemantic proximity Read ↗

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment OptionsSemantic proximity Read ↗

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathwaySemantic proximity Read ↗

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repairSemantic proximity Read ↗

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer CellsSemantic proximity Read ↗

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer modelsSemantic proximity Read ↗

ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian CancerSemantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.